Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuwellis, Inc. filings document a Nasdaq-listed medical technology issuer focused on cardiorenal care and ultrafiltration therapy. Form 8-K reports cover operating results, material events, clinical or regulatory disclosures, board appointments and resignations, and resolved litigation matters, while proxy materials describe director elections, auditor ratification, board committee governance, executive compensation, and stockholder voting matters.
Nuwellis, Inc. filed a resale registration covering up to 4,279,325 shares of common stock issuable from previously issued warrants held by selling stockholders. These shares come from January 2026 pre-funded warrants, common stock purchase warrants, January inducement warrants, and placement agent warrants.
Nuwellis will not sell shares directly in this offering and will not receive proceeds from stockholder resales, but may receive up to approximately $28 million if all registered warrants are exercised for cash. As of January 31, 2026, Nuwellis had 1,873,892 shares of common stock outstanding, before any warrant exercises.
Nuwellis, Inc. entered a securities purchase agreement for a private placement of pre-funded and common stock warrants, raising approximately $3.1 million in gross proceeds to support working capital and general corporate purposes. The company also induced an investor to immediately exercise certain existing warrants at a reduced exercise price, generating approximately $2 million of additional gross proceeds and issuing new five-year common stock purchase warrants. As of January 29, 2026, Nuwellis had 1,686,892 shares of common stock outstanding.
Nuwellis agreed to acquire all shares of Rendiatech, Ltd., which holds assets from RenalSense’s bankruptcy, for a mix of cash, 150,000 Nuwellis shares, options to purchase 30,000 shares, additional deferred cash payments, and up to $2,000,000 in earn-out royalties tied to sales of kidney monitoring products. The transaction is subject to closing conditions, including Israeli tax approval. The company also appointed Carisa Schultz as Chief Financial Officer, effective February 2, 2026, with a base salary of $265,000 and eligibility for an annual bonus of up to 40% of base salary and standard change-in-control and indemnification protections.
Nuwellis, Inc. reported significant board changes. On January 21, 2026, directors Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the board and all committees. The company states these resignations were not due to any disagreement over operations, policies, or practices, and the board size was reduced from six to five members.
Effective the same day, the board appointed Katharyn Field and Mika Grasso as Class I directors, with terms running until the 2026 annual meeting. The board determined both are independent under Nasdaq, internal policy, and SEC standards. Field is expected to join the Audit and Compensation Committees, while Grasso is expected to join the Audit and Nominating and Corporate Governance Committees.
Both new directors entered into Nuwellis’ standard indemnity agreement and are eligible under the Non-Employee Director Compensation Program. Each has agreed to resign if an investment of at least $5 million in the company’s equity securities is not made within 30 days of the filing of a related Form S-1 registration statement, or within 30 days of clearing any SEC comments on that filing.
Nuwellis, Inc. reported a new 5%+ shareholder group in its common stock. Sabby Volatility Warrant Master Fund, Ltd., together with Sabby Management, LLC and Hal Mintz, filed a Schedule 13G showing beneficial ownership of 89,685 shares of Nuwellis common stock, or 5.41% of the class as of the event date. The filing states that all three reporting persons share voting and dispositive power over these shares and that none has sole voting or dispositive authority.
The investors certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Nuwellis, but instead are being reported under the passive ownership framework used for Schedule 13G filers.
Nuwellis (NUWE) filed its Q3 2025 10‑Q. Net sales were $2.217 million, down from $2.367 million a year ago, as lower console pricing and reduced international activity offset a 15% increase in circuit sales. Gross margin was 65.2% versus 70.0% last year. The company reported quarterly net income of $468,000, aided by a $3.161 million non‑cash gain from the change in fair value of warrant liabilities.
Year‑to‑date, net sales were $5.846 million versus $6.418 million and net loss was $15.099 million. Operating cash flow for the nine months was an outflow of $7.780 million. Cash and cash equivalents were $3.094 million as of September 30, 2025. Management states that existing capital resources are expected to support operations into the first quarter of 2026, while acknowledging “substantial doubt” about the ability to continue as a going concern.
During the quarter, Nuwellis closed a June public offering with approximately $5.0 million in gross proceeds, executed a 1‑for‑42 reverse stock split effective July 3, 2025, and launched an ATM program, selling 447,288 shares for about $1.9 million in net proceeds by September 30. The company exited selected international operations (with about $254,000 accrued for related obligations), terminated the REVERSE‑HF clinical trial (anticipated savings of approximately $4.0 million over 2.5 years), and transitioned manufacturing to KDI to streamline operations.
Nuwellis, Inc. filed a report noting that on November 12, 2025 it released a press release with its financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company states that this financial information is being furnished under Item 2.02 of Form 8-K, rather than filed, which limits how it is treated under certain securities law liability provisions.
Nuwellis, Inc. reported that its Chief Financial Officer, Robert B. Scott, has decided to resign, with his last day expected on or about October 24, 2025. The company states that his resignation is not due to any disagreement regarding operations, policies, or procedures, and it plans to begin a formal search for a new CFO.
To bridge the gap, the Board has appointed current President and Chief Executive Officer John L. Erb to also serve as interim Chief Financial Officer, interim Principal Financial Officer, and interim Principal Accounting Officer beginning on the separation date. Erb, who has long experience with Nuwellis and multiple medical device companies, will receive no additional compensation for these interim roles, and there are no special arrangements or related-party transactions tied to his appointment.
Nuwellis, Inc. filed a current report describing a clinical research update. On September 30, 2025, the company announced findings from the ULTRA-Peds registry, a multi-center observational study.
The registry examines real-world use of the company’s Aquadex System in children with acute kidney injury, fluid overload, or congenital kidney failure. The update focuses on clinical experience in pediatric patients rather than on financial or transactional developments.
Nuwellis, Inc. reported that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021, dated September 16, 2025, based on Application No. 18/298,860.
The patent covers the use of one or more hemolysis sensors with extracorporeal blood filtration systems, including ultrafiltration therapy and continuous renal replacement therapy, to help detect and localize red blood cell destruction in or around the circuit.
This intellectual property is described as supporting Nuwellis’ pediatric device, Vivian, which is in development, as well as future platform innovation.
Nuwellis, Inc. reported that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021, dated September 16, 2025, based on Application No. 18/298,860.
The patent covers the use of one or more hemolysis sensors with extracorporeal blood filtration systems, including ultrafiltration therapy and continuous renal replacement therapy, to help detect and localize red blood cell destruction in or around the circuit.
This intellectual property is described as supporting Nuwellis’ pediatric device, Vivian, which is in development, as well as future platform innovation.
Nuwellis announced that the National Institutes of Health awarded an approximately $3 million multi-year grant to Koronis Biomedical Technologies Corporation (KBT), its development partner. The NIH funding is directed to accelerate Vivian™, the pediatric continuous renal replacement therapy (CRRT) device in development for patients under 20 kilograms, and to advance core software and firmware that support Nuwellis’ broader device portfolio. The filing states the award aims to speed development of the pediatric product and strengthen underlying technology, but does not specify how funds will be allocated between KBT and Nuwellis or any timeline or financial impact on Nuwellis’ statements.